Researchers at Imperial College London will explore the potential for Filament's botanical psilocybin drug candidate to aid in treating opioid use disorder as part of a landmark trial.
A ‘first in the UK’ clinical trial exploring the use of psychedelics in addiction has won funding from the National Institute for Health Research (NIHR) and the Government’s Office for Life Sciences.
The trial, led by Imperial College London, will focus on whether psilocybin – the active compound in magic mushrooms – combined with psychological support, can help to prevent relapse in people who have been addicted to opioids such as heroin.
